SCHEMBL30855264

SCHEMBL30855264

CC(C)(C)OC(=O)N1CCC(O)(CCCO)C1

nearest known ligand 0.49

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 1/20 0.49
CYP4A11 Q02928 1/20 0.49
USP2 O75604 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NR1H2 P55055 1/20 0.39
GPR4 P46093 1/20 0.39
CYP11B2 P19099 1/20 0.37
USP30 Q70CQ3 1/20 0.37
SCD5 Q86SK9 1/20 0.36
HPGD P15428 1/20 0.35
EPHX2 P34913 1/20 0.35
GPR119 Q8TDV5 3/20 0.35
ACACB O00763 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1575709 0.93 CYP4F2 (0.47) CYP4F2CYP4A11USP2SMN1; SMN2NR1H2
SCHEMBL7169881 0.91 CYP4F2 (0.46) CYP4F2CYP4A11USP2SMN1; SMN2NR1H2
SCHEMBL3318268 0.91 CYP4F2 (0.45) CYP4F2CYP4A11USP2SMN1; SMN2NR1H2
SCHEMBL2954455 0.89 CYP4F2 (0.43) CYP4F2CYP4A11USP2SMN1; SMN2NR1H2
SCHEMBL26044480 0.87 CYP4F2 (0.42) CYP4F2CYP4A11USP2SMN1; SMN2NR1H2
SCHEMBL20812730 0.87 CYP4F2 (0.54) CYP4F2CYP4A11USP2SMN1; SMN2NR1H2
SCHEMBL16553663 0.86 USP2 (0.44) CYP4F2CYP4A11USP2SMN1; SMN2NR1H2
SCHEMBL30959377 0.84 USP2 (0.51) CYP4F2CYP4A11USP2SMN1; SMN2NR1H2
SCHEMBL31447849 0.84 USP2 (0.41) CYP4F2CYP4A11USP2SMN1; SMN2NR1H2
SCHEMBL24012274 0.83 USP2 (0.44) CYP4F2CYP4A11USP2SMN1; SMN2NR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4594294-A1 DOPAMINE D3/D2 RECEPTOR PARTIAL AGONISTS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS The United States of America, as represented by the Secretary, Department of Health and Human Services (US) 2025-08-06 EP disclosed
WO-2024072930-A1 DOPAMINE D3/D2 RECEPTOR PARTIAL AGONISTS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2024-04-04 WO disclosed